TY  - JOUR
AU  - Casali, P G
AU  - Le Cesne, A
AU  - Velasco, A P
AU  - Kotasek, D
AU  - Rutkowski, P
AU  - Hohenberger, P
AU  - Fumagalli, E
AU  - Judson, I R
AU  - Italiano, A
AU  - Gelderblom, H
AU  - Penel, N
AU  - Hartmann, J T
AU  - Duffaud, F
AU  - Goldstein, D
AU  - Martin-Broto, J
AU  - Gronchi, A
AU  - Wardelmann, E
AU  - Marréaud, S
AU  - Zalcberg, J R
AU  - Litière, S
AU  - Blay, J-Y
PY  - 2021
DO  - 10.1016/j.annonc.2021.01.004
UR  - https://hdl.handle.net/10668/27221
T2  - Annals of oncology : official journal of the European Society for Medical Oncology
AB  - In 2004, we started an intergroup randomized trial of adjuvant imatinib versus no further therapy after R0-R1 surgery in localized, high/intermediate-risk gastrointestinal stromal tumors (GIST) patients. Interim analysis results were published in 2015...
LA  - en
KW  - adjuvant
KW  - gastrointestinal stromal tumors (GIST)
KW  - imatinib
KW  - Antineoplastic Agents
KW  - Chemotherapy, Adjuvant
KW  - Gastrointestinal Neoplasms
KW  - Gastrointestinal Stromal Tumors
KW  - Humans
KW  - Imatinib Mesylate
KW  - Italy
KW  - Neoplasm Recurrence, Local
KW  - Sarcoma
TI  - Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)☆.
TY  - research article
VL  - 32
ER  -